DiaMedica Therapeutics Inc
NASDAQ:DMAC
Intrinsic Value
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of DMAC.
DiaMedica Therapeutics Inc's market capitalization is 94.5m USD.
DMAC stock price is 2.49 USD.
DMAC.
DMAC. Open DCF Valuation
DMAC. Open Relative Valuation
DMAC has upside potential of 187% compared to the average analyst price target.
Open Wall St Estimates
DMAC has negative Free Cash Flow for the last twelve months.
DMAC has negative Operating Income for the last twelve months.
DMAC has negative Net Income for the last twelve months.
DMAC's ROE (Return on Equity) has significantly increased in the last 3 years from -74% to -47%, and is approaching profitability.
DMAC's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -1 800% to -8 375%, and is approaching profitability.
DMAC's ROE (Return on Equity) for the past 12 months is negative and is equal to -47%.
DMAC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -8 375%.
DMAC has negative three-year average ROE (Return on Equity): -49%. The company is not efficient at transforming stockholders' equity into net income.
DMAC has very high three-year average ROIC (Return on Invested Capital): 1 388%. The company is very efficient at using invested capital to generate operating income.
DMAC's short-term assets (54m USD) exceed its short-term liabilties (3m USD).
DMAC's long-term assets (54m USD) exceed its long-term liabilties (3m USD).
DMAC has negative Net Debt. This means that the company has more cash and short-term investments (53m USD) than debt (1k USD).
DMAC's D/E (Debt to Equity) is very low and is equal to 0.
DMAC's Altman Z-Score is very high and is equal to 16.52.
Fundamental Analysis
DiaMedica Therapeutics Inc
Balance Sheet Decomposition
DiaMedica Therapeutics Inc
| Current Assets | 53.7m |
| Cash & Short-Term Investments | 52.9m |
| Receivables | 369k |
| Other Current Assets | 411k |
| Non-Current Assets | 485k |
| PP&E | 485k |
| Current Liabilities | 2.8m |
| Accounts Payable | 926k |
| Accrued Liabilities | 1.9m |
| Other Current Liabilities | 3k |
| Non-Current Liabilities | 317k |
| Long-Term Debt | 1k |
| Other Non-Current Liabilities | 316k |
Earnings Waterfall
DiaMedica Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-21.3m
USD
|
|
Operating Income
|
-21.3m
USD
|
|
Other Expenses
|
1.9m
USD
|
|
Net Income
|
-19.4m
USD
|
Free Cash Flow Analysis
DiaMedica Therapeutics Inc
What is Free Cash Flow?
DMAC Profitability Score
Profitability Due Diligence
DiaMedica Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
DiaMedica Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
DMAC Solvency Score
Solvency Due Diligence
DiaMedica Therapeutics Inc's solvency score is 88/100. The higher the solvency score, the more solvent the company is.
Score
DiaMedica Therapeutics Inc's solvency score is 88/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DMAC Price Targets Summary
DiaMedica Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
DMAC
is 7.14 USD
with a low forecast of 6.06 USD and a high forecast of 8.4 USD.
Ownership
DMAC Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
DMAC Price
DiaMedica Therapeutics Inc
| Average Annual Return | 6.58% |
| Standard Deviation of Annual Returns | 82.91% |
| Max Drawdown | -89% |
| Market Capitalization | 94.5m USD |
| Shares Outstanding | 37 958 000 |
| Percentage of Shares Shorted | 0.85% |
Company Profile
DiaMedica Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
You don't have any saved screeners yet
